- Home
- MIN vs MREO Comparison
MIN vs MREO Comparison
Compare MIN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- MREO
- Stock Information
- Founded
- MIN 1988
- MREO 2015
- Country
- MIN United States
- MREO United Kingdom
- Employees
- MIN N/A
- MREO N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- MIN Finance
- MREO Health Care
- Exchange
- MIN Nasdaq
- MREO Nasdaq
- Market Cap
- MIN 303.8M
- MREO 311.8M
- IPO Year
- MIN N/A
- MREO N/A
- Fundamental
- Price
- MIN $2.61
- MREO $2.08
- Analyst Decision
- MIN
- MREO Strong Buy
- Analyst Count
- MIN 0
- MREO 5
- Target Price
- MIN N/A
- MREO $7.40
- AVG Volume (30 Days)
- MIN 331.0K
- MREO 1.6M
- Earning Date
- MIN 01-01-0001
- MREO 11-12-2025
- Dividend Yield
- MIN 7.31%
- MREO N/A
- EPS Growth
- MIN N/A
- MREO N/A
- EPS
- MIN 0.08
- MREO N/A
- Revenue
- MIN N/A
- MREO $500,000.00
- Revenue This Year
- MIN N/A
- MREO N/A
- Revenue Next Year
- MIN N/A
- MREO $72.16
- P/E Ratio
- MIN $33.38
- MREO N/A
- Revenue Growth
- MIN N/A
- MREO N/A
- 52 Week Low
- MIN $2.52
- MREO $1.47
- 52 Week High
- MIN $2.88
- MREO $4.40
- Technical
- Relative Strength Index (RSI)
- MIN 35.63
- MREO 55.00
- Support Level
- MIN $2.63
- MREO $1.98
- Resistance Level
- MIN $2.68
- MREO $2.28
- Average True Range (ATR)
- MIN 0.02
- MREO 0.12
- MACD
- MIN -0.00
- MREO -0.01
- Stochastic Oscillator
- MIN 12.50
- MREO 39.40
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).